Frederique M. Llorca-Penault
Elite in Breast Cancer

Frederique M. Llorca-Penault

Clermont-ferrand, FR 
Elite in Breast Cancer
Clermont-ferrand, FR 
OverviewLocationsClinical Research

Overview

Frederique Llorca-Penault practices in Clermont-ferrand, France. Ms. Llorca-Penault is rated as an Elite expert by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Lung Cancer, Oophorectomy, and Mastectomy.

Her clinical research consists of co-authoring 334 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 200 articles and participated in 2 clinical trials in the study of Breast Cancer.

Gender
Female

Locations

Clermont-ferrand, France
Other Locations
Paris, France
Montpellier, France
Nice, 63000, France
Saint-jean-saint-germain, France
Villejuif, France
U1240, Imagerie Moléculaire Et Stratégies Théranostiques, 28 Place Henri Dunant, BP38-, Clermont, Ferrand, 63001, France
Unicancer, France
Lyon, France
Aubiere, 63172, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Multicenter Large-scale Validation Study of the Interest of Broadband Spectroscopy Analysis (Femto/Attosecond by Infrared Laser) on Liquid Biopsies in Breast Cancer Screening
Multicenter Large-scale Validation Study of the Interest of Broadband Spectroscopy Analysis (Femto/Attosecond by Infrared Laser) on Liquid Biopsies in Breast Cancer Screening
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Other
Study Phase: Not Applicable
Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm.
Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm.
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
View 1 Less Clinical Trial

334 Total Publications

Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Llorca-Penault's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile